Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Erythropoiesis01:14

Erythropoiesis

5.3K
Red blood cells  (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia,...
5.3K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

621
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
621
Disorders of Leukocytes01:27

Disorders of Leukocytes

1.5K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of prognostic factors and outcomes in primary versus secondary myeloid sarcoma.

Human pathology·2026
Same author

Deletion 11q, monosomy 13, and deletion 13q in noncomplex karyotype acute myeloid leukemia.

Blood neoplasia·2026
Same author

Acute leukemias with expression of CD56.

American journal of clinical pathology·2026
Same author

Hematolymphoid neoplasms involving the breast: A single institution clinicopathologic study of 59 patients.

Annals of hematology·2026
Same author

Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial.

Blood neoplasia·2026
Same author

Distinct Pattern of Atypical Megakaryocytes in VEXAS Syndrome.

International journal of laboratory hematology·2026
Same journal

Next-Generation Checkpoint Combinations: Optimizing PD-(L)1-Based Therapy Across the Advanced, Adjuvant, and Neoadjuvant Settings.

Current oncology reports·2026
Same journal

Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology.

Current oncology reports·2026
Same journal

Anti-PD-1 Combinations: Triplets and Beyond.

Current oncology reports·2026
Same journal

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Current oncology reports·2026
Same journal

Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications.

Current oncology reports·2026
Same journal

Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.

Current oncology reports·2026
See all related articles

Related Experiment Video

Updated: Nov 8, 2025

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.9K

Erythroleukemia: an Update.

Olga K Weinberg1, Daniel A Arber2

  • 1Department of Pathology, University of Texas Southwestern Medical Center, BioCenter, 2230 Inwood Rd, EB03.220G, Dallas, TX, 75235, USA. Olga.weinberg@UTSouthwestern.edu.

Current Oncology Reports
|April 20, 2021
PubMed
Summary
This summary is machine-generated.

Acute erythroleukemia (AEL) is a rare leukemia subtype. Recent findings clarify AEL diagnosis, highlighting distinct genetic mutations and potential therapeutic targets like hypomethylating agents.

Keywords:
Acute erythroid leukemiaClinical presentationGenomicsMolecular mutations

More Related Videos

Assessment of the Metabolic Profile of Primary Leukemia Cells
06:21

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

10.7K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.3K

Related Experiment Videos

Last Updated: Nov 8, 2025

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.9K
Assessment of the Metabolic Profile of Primary Leukemia Cells
06:21

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

10.7K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.3K

Area of Science:

  • Hematology
  • Oncology
  • Leukemia Research

Background:

  • Acute erythroleukemia (AEL) is a rare subtype of acute myeloid leukemia (AML) characterized by erythroblastic proliferation.
  • Diagnostic criteria and prognostic implications for AEL remain areas of ongoing research and debate.
  • Understanding AEL's unique characteristics is crucial for optimizing patient outcomes.

Purpose of the Study:

  • To review the evolving diagnostic concepts of erythroleukemia.
  • To discuss the genomics, clinical outcomes, and therapeutic targets in AEL.
  • To provide an appraisal of the current literature on this leukemia subset.

Main Methods:

  • Literature review and appraisal of current scientific publications.
  • Analysis of diagnostic criteria based on the 2016 WHO classification.
  • Examination of mutational data and karyotype abnormalities in AEL.

Main Results:

  • The 2016 WHO classification offers more restrictive diagnostic criteria for AEL.
  • Primary acute erythroid leukemia frequently presents with complex, high-risk karyotypes, including 5q and 7q abnormalities.
  • AEL exhibits lower rates of NPM1 and FLT3-ITD mutations and higher TP53 mutation rates compared to other AML subtypes.
  • Hypomethylating agents have demonstrated therapeutic efficacy in AEL.

Conclusions:

  • Evolving diagnostic criteria are refining the understanding of AEL.
  • Genomic profiling reveals distinct mutational patterns in AEL, differentiating it from other AMLs.
  • Targeted therapies, including hypomethylating agents, show promise for AEL treatment.